prikaz prve stranice dokumenta GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease
Rad je dostupan svim korisnicima iz sustava znanosti i visokog obrazovanja RH
Znanstveni rad - Pregledni rad
GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease
Cochrane Database of Systematic Reviews, 2024 (2024), 12; CD015826. https://doi.org/10.1002/14651858.CD015826
Aralica, Merica; Nadarevic, Tin; Colli, Agostino; Casazza, Giovanni; Vranić, Luka; Fraquelli, Mirella; Poropat, Goran; Štimac, Davor

Citiranost:
,
Citirajte ovaj rad

Aralica, M., Nadarevic, T., Colli, A., Casazza, G., Vranić, L., Fraquelli, M. ... Štimac, D. (2024). GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease. Cochrane Database of Systematic Reviews, 2024. (12). doi: 10.1002/14651858.CD015826

Aralica, Merica, et al. "GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease." Cochrane Database of Systematic Reviews, vol. 2024, br. 12, 2024. https://doi.org/10.1002/14651858.CD015826

Aralica, Merica, Tin Nadarevic, Agostino Colli, Giovanni Casazza, Luka Vranić, Mirella Fraquelli, Goran Poropat i Davor Štimac. "GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease." Cochrane Database of Systematic Reviews 2024, br. 12 (2024). https://doi.org/10.1002/14651858.CD015826

Aralica, M., et al. (2024) 'GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease', Cochrane Database of Systematic Reviews, 2024(12). doi: 10.1002/14651858.CD015826

Aralica M, Nadarevic T, Colli A, Casazza G, Vranić L, Fraquelli M, i sur.. GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease. Cochrane Database of Systematic Reviews [Internet]. 17.12.2024. [pristupljeno 31.03.2025.];2024(12). doi: 10.1002/14651858.CD015826

M. Aralica, et al., "GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease", Cochrane Database of Systematic Reviews, vol. 2024, br. 12, Prosinac 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:223952. [Citirano: 31.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:223952
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease
AutorMerica Aralica
AutorTin Nadarevic
AutorAgostino Colli
AutorGiovanni Casazza
AutorLuka Vranić
AutorMirella Fraquelli
AutorGoran Poropat
AutorDavor Štimac
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za radiologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Objectives: This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows:. To estimate the diagnostic accuracy of des-gamma-carboxy prothrombin, GALAD (Gender, Age, Lens culinaris agglutinin-reactive AFP, AFP and DCP), and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma of any size, and at any stage, in adults with chronic liver disease, in either a surveillance programme or a clinical setting. We acknowledge the possibility that theoretically, the... Više accuracy of the tests in a surveillance programme may differ from that in a clinical setting due to variation in inclusion criteria and the prevalence of the target condition. However, we do not plan a separate analysis for surveillance and clinical settings, as they are not clearly distinct in current clinical practice (Forner 2018; Poustchi 2011). In routine evaluation of people with chronic liver disease, index tests, as well as ultrasound, are already part of standard procedure. Given that HCC typically presents with no symptoms and is often asymptomatic, suspicion of the disease is typically based solely on the presence of advanced chronic liver disease. However, we do plan to consider the study setting as a potential source of heterogeneity. To compare the diagnostic accuracy of des-gamma-carboxy prothrombin (DCP) alone or GALAD alone versus alpha-foetoprotein (AFP), for the diagnosis of hepatocellular carcinoma (HCC) of any size, at any stage; in adults with chronic liver disease, either in a surveillance programme or a clinical setting. Secondary objectives To estimate the diagnostic accuracy of DCP or GALAD versus AFP, for resectable HCC in people with chronic liver disease, in a surveillance programme and a clinical setting. To investigate the following predefined sources of heterogeneity for each of the index tests: study design (case-control studies compared to cross-sectional studies); inclusion of participants without cirrhosis (studies including more than 10% of participants without cirrhosis compared to studies including less than 10% of participants without cirrhosis); study location (population differences): studies conducted in North and South America and Europe compared to Asia and Africa; prevalence of the target condition (studies with hepatocellular carcinoma prevalence more than 10% compared to studies with hepatocellular carcinoma prevalence less than 10%); participant selection (participants recruited from planned surveillance programmes compared to clinical cohorts); different reference standards (histology of the explanted liver compared to liver biopsy compared to another reference standard); different aetiology: studies including at least 90% of participants with chronic viral hepatitis compared to studies including less than 90% of participants with chronic viral hepatitis. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCochrane Database of Systematic Reviews
Brojčani podacivol. 2024, br. 12, CD015826
e-ISSN1465-1858
DOIhttps://doi.org/10.1002/14651858.CD015826
URN:NBNurn:nbn:hr:184:223952
Datum objave publikacije2024-12-17
URL dokumentahttp://doi.wiley.com/10.1002/14651858.CD015826
Vrsta resursaTekst
Prava pristupaOgraničen pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2025-03-05 12:38:57
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.